IXICO to Present at Innovation Forum

RNS Number : 4717C

IXICO plc

10 February 2020

 

 10 February 2020

IXICO plc

("IXICO" or the "Company")

IXICO to Present at the Annual Shares Magazine/Cenkos Growth and Innovation Forum

on 11^th February 2020

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that the Company will be attending and presenting at the Shares Magazine/Cenkos Growth and Innovation Forum on Tuesday, 11 February 2020 at the London Business Design Centre.

Giulio Cerroni, IXICO's Chief Executive Officer, will be attending the event and presenting at 12:15pm GMT in the Flowers Room.

Shares Magazine/Cenkos Growth and Innovation Forum: 

Presentation: 12:15 PM GMT, 11 February 2020, Flowers Room

Exhibition: 09:00 AM - 5:00 PM GMT, 11 February 2020, Booth 25

London - Business Design Centre, London N1 52 Upper Street, Islington

The Shares Magazine/Cenkos Growth and Innovation Forum is one of the UK's major growth and technology focussed investment shows connecting investment experts, fund managers, company executives from fast-growing and technology-led London-listed companies.

For further information please contact:

IXICO plc	[phone]
Alison Howie, Chief Product Officer
Optimum Strategic Communications	[phone]
Mary Clark / Supriya Mathur / Manel Mateus
[e-mail]

About IXICO

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.

Our goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available on www.IXICO.com

 

END

 

 

NRAVBLBFBLLEBBV